Morgan Stanley Maintains Equal-Weight on Foghorn Therapeutics, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Foghorn Therapeutics (NASDAQ:FHTX) and raises the price target from $6 to $9.
September 24, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has increased the price target for Foghorn Therapeutics from $6 to $9, maintaining an Equal-Weight rating. This suggests a positive outlook on the stock's potential performance.
The increase in price target from $6 to $9 by Morgan Stanley indicates a positive reassessment of Foghorn Therapeutics' potential, which could lead to a short-term increase in stock price as investors react to the new target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100